Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADX-626 in Healthy Participants
NCT07081503Phase 1Recruiting
- Sponsor
- ADARx Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- Jan 2027
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in thrombosis comparing ADX-626 with Placebo (2 arms). Primary endpoint: Safety and Tolerability of ADX-626. Started Aug 2025; status: recruiting.
02
Drugs
ADX-626
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT07081503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07081503.